GlaxoSmithKline plc (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 165   

Articles published

GSK 39.70 -0.26 (-0.65%)
price chart
Analytic Report on GlaxoSmithKline PLC (ADR) (NYSE:GSK)
[Financial Times] GlaxoSmithKline PLC (ADR) (NYSE:GSK)(TREND ANALYSIS) Broker theorising about a �90bn takeover was greeted with a shrug by GlaxoSmithKline shareholders.
GlaxoSmithKline plc (ADR) Mega-Merger Talk: Johnson & Johnson, Roche Holding ...
New takeover rumors for GlaxoSmithKline Plc. (ADR) (NYSE:GSK) emerged Monday. Daily Mail UK reported that UK dealers were speculating Roche Holding Ltd.
British ADRs To Look Out For: GlaxoSmithKline plc (ADR) (NYSE:GSK ...
The Footsie extended its falls to over 1 per cent as the morning session progressed, losing a big chunk of Friday's strong rally in tandem with weaker Asian markets after further disappointing economic data from China, with European markets also ...
GlaxoSmithKline plc (ADR) Reiterated As “Hold” At Deutsche Bank: Here's Why
British pharmaceutical giant, GlaxoSmithKline plc (ADR) (NYSE:GSK) has been reiterated as a “Hold” at Deutsche Bank, in a recent report published on Thursday, September 10.
GlaxoSmithKline plc. (ADR) (GSK) Sells Two Meningitis Vaccines To Pfizer Inc ...
The need for the said transaction arose, as GSK sought to ease the concerns of regulatory authorities. The company has recently acquired Novartis's NoMenveo and Bexsero vaccines.
Here's How Pfizer Inc., GlaxoSmithKline plc Vaccines Deal Works For Both ...  Bidness ETC
GSK Vaccinates Pfizer to Gain Novartis
Will GlaxoSmithKline plc (ADR) (GSK) Stock Bounce Back After Yesterday's Crash?
GlaxoSmithKline plc (ADR) (NYSE:GSK), the British pharmaceutical giant, after seeing miserable performance due to declining revenues as its major blockbuster drugs lost patents is in troubled waters again.
GlaxoSmithKline plc (ADR) Loses Hope Of Regaining Lost Advair Sales; New Drug ...
GlaxoSmithKline plc. (ADR) (NYSE:GSK) announced on Tuesday that its respiratory treatment Breo Ellipta failed to prolong patients' life in a large-scale clinical trial, further complicating the British drug-maker's attempts to maintain lead in the ...
Theravance Just Lost Its Catalyst  Benzinga
GlaxoSmithKline plc (ADR) (GSK) Q2 Revenues Rise, Beat Expectations
British pharmaceutical giant GlaxoSmithKline plc (ADR) (NYSE:GSK) announced second-quarter fiscal'15 earnings before the market opened today, reporting better-than-expected earnings and revenues.
Glaxo Up on Q2 Earnings Beat, Revenues Rise, View Same
Glaxo Up on Q2 Earnings Beat, Revenues Rise, View Same - Analyst Blog  Nasdaq
British Stocks Trading on US Exchanges: GlaxoSmithKline plc (ADR) (NYSE:GSK ...
Britain's top share index fell on Friday, led lower by weakness in retail stocks, with the focus on U.S. jobs data later in the session that could provide clues about when the Federal Reserve might raise interest rates.
Drug Manufacturers Of Interest - AbbVie Inc. (NYSE:ABBV), Merck & Co ...  Wall Street Observer
News Review - GlaxoSmithKline (GSK), Catalent (CTLT), Time Warner Cable (TWC ...  Techsonian (press release)
Gilead Sciences, Inc. Vs. GlaxoSmithKline plc (ADR) In The HIV Drugs Race
Gilead Sciences, Inc. (NASDAQ:GILD), the undisputed leader of the fast-expanding Hepatitis C drugs market, is headed for dominating the HIV market as well.